TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00440895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
Study: NCT04325945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: 808nm low level laser therapy on acupuncture points

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low level laser therapy
Description: 808nm low level laser therapy on acupuncture points
Study: NCT00828334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter PDA Coil
Description: The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
Study: NCT04242238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3014
Description: DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Start Day 1 on first cycle with further infusions of avelumab every 14 days
Study: NCT04275050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3303
Description: TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
Study: NCT00369395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volociximab
Description: Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
Study: NCT00013481

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stroke Rehabilitation
Study: NCT04568031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
Study: NCT01224236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron as multivitamin with iron solution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: multivitamin solution without iron
Study: NCT00570531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
Study: NCT03919968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Martial Arts
Description: The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
Study: NCT03882398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance
Description: Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)
Study: NCT01794013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent training
Description: All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: routine care
Study: NCT02779673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing plant stanol as esters

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt drink without plant stanol as esters
Study: NCT01123226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
Study: NCT01376726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sub C gp140 Vaccine
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sub C gp140 Vaccine
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1 Adjuvant
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1 Adjuvant
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.
Study: NCT01123226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point therapy
Description: The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
Study: NCT04161690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: intravenous dexketoprofen 50mg or intrathecal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: intravenous dexketoprofen 50mg or intrathecal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: Local Infiltration Analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: Local Infiltration Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: Local Infiltration Analgesia
Study: NCT01936883

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR
Description: High dose rate brachytherapy
Study: NCT03655574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational + Family Check-up (MET+FCU)
Description: In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation about substances is provided to teens and parents.
Study: NCT01936883

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LDR
Description: Low dose rate brachytherapy boost
Study: NCT04123301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Theta Burst Stimulation (TBS)
Description: Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
Study: NCT04375241

Intervention type: OTHER
Intervention: Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Description: Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Study: NCT01237561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: provider support tools plus spirometer
Description: Patient Activation Tool, Provider Web-based decision support tool, academic detailing
Study: NCT04387318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal training
Description: IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT + Pulmonary Rehabilitation
Description: IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES + Pulmonary Rehabilitation
Description: NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Study: NCT04568031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% (w/v) saline
Description: For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
Study: NCT02527018

Intervention type: DEVICE
Intervention: Sphygmomanometer
Description: Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.

Intervention type: DEVICE
Intervention: Sphygmomanometer
Description: Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
Study: NCT01884428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
Study: NCT02575976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive CR
Description: In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise-based CR
Description: The main program is 6 months in duration, with 36 1-hour exercise sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: wait list control
Description: No cardiac rehabilitation.
Study: NCT02660528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous tocilizumab
Study: NCT01892657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer with SPF 50+
Description: All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
Study: NCT01124357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovaSure
Description: Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..

Intervention type: DEVICE
Group type: OTHER
Intervention: thermachoice
Description: ThermachoiceTM III thermal balloon ablation
Study: NCT02719106

Intervention type: DEVICE
Intervention: Ultimaster stent
Study: NCT00031122

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this study
Study: NCT03221348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHO-H01
Description: Glyco-engineered anti-CD20 antibody
Study: NCT03308539

Intervention type: RADIATION
Intervention: echocardiography and cardiac magnetic resonance
Description: transthoracic echocardiography and magnetic resonance imaging of the heart
Study: NCT04714229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine
Description: 0.5mL single intramuscular dose on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
Description: 0.5mL single intramuscular dose on Day 0
Study: NCT02497313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystokinin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystokinin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01677923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg BID for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg BID for 12 months
Study: NCT04030182

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Vitamin D
Description: 3 ml of venous blood will be taken to determine the level of vitamin D
Study: NCT02375919

Intervention type: OTHER
Group type: OTHER
Intervention: PERC based Strategy
Description: work up for diagnosis of PE includes calculation of PERC
Study: NCT02063243

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intralesional cryotherapy
Description: Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
Study: NCT02622113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study: NCT02592109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counseling using CFR based on Linear Programming

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Counseling using CFR based on Linear Programming
Study: NCT02575274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical flaps
Description: Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical flaps
Description: Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.